Late gadolinium enhancement CMR for detecting myocardial injury after cancer therapy: a real-world observational study
Open Access
- 1 May 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1787820
Abstract
Background: Clinically, cardiotoxicity defined by reduced left ventricle ejection fraction (LVEF) in cancer therapy could miss the onset of tissue-level myocardial changes. In this study, we aimed to use late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) to evaluate myocardial injury in patients receiving cancer therapy, and to investigate the effect of LGE and other clinical factors on LV function. Methods: This study included 108 cancer patients and 60 healthy controls examined by CMR imaging. Patients were assigned to the LGE-negative (LGE−, n = 80) and LGE-positive groups (LGE+, n = 28). The LV functional parameters and myocardial strain parameters, were compared among the three subgroups. Associations between variables were evaluated via Pearson or Spearman correlation analyses. Further, the association between risk factors and LVEF was determined via multivariate linear regression analysis. Results: The LVEF and peak strain (PS) in all directions were significantly lower in the patients with LGE than in those without (all p < 0.05). There were moderate to high correlations between circumferential peak diastolic strain rate (PDSR), peak systolic strain rate (PSSR), PS, and LVEF in the patients with cancer ( r = 0.54, r = −0.63, r = 0.82, respectively; p < 0.001). Multivariate linear regression analysis revealed independent associations between 1) N-terminal-pro B-type natriuretic peptide and radial, circumferential and longitudinal PS ( β = −0.419, β = 0.407, β = 0.327, respectively; p < 0.001), 2) troponin T and circumferential PDSR ( β = 0.342, p < 0.001) and between 3) the LGE extent (LGE%, 5SD) and circumferential PS ( β = 0.297, p < 0.001). Conclusions: The presence of LGE was an important risk factor for LV dysfunction in patients receiving cancer therapy, and the circumferential strain reduction is the predominant mechanism of LV dysfunction.Keywords
This publication has 29 references indexed in Scilit:
- Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicityHeliyon, 2023
- Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated CardiotoxicityJAMA Oncology, 2023
- Cardiac magnetic resonance T1 mapping for evaluating myocardial fibrosis in patients with type 2 diabetes mellitus: correlation with left ventricular longitudinal diastolic dysfunctionEuropean Radiology, 2022
- Strain-Guided Management of Potentially Cardiotoxic Cancer TherapyJACC, 2021
- Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)European Journal of Heart Failure, 2020
- Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced CardiotoxicityJACC, 2019
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected MyocarditisJACC, 2017
- Late Anthracycline-Related Cardiotoxicity in Low-Risk Breast Cancer PatientsJACC, 2017
- Assessment of Left Ventricular Function by Layer-Specific Strain and Its Relationship to Structural Remodelling in Patients With HypertensionCanadian Journal of Cardiology, 2016